Market Overview:
The global fatty liver treatment market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The market growth is attributed to the increasing prevalence of fatty liver disease, rising awareness about the available treatments, and technological advancements in the field of fatty liver treatment. Based on type, the global fatty liver treatment market is segmented into thiazolidinedione, vitamin E, metformin statins, polyunsaturated fatty acids (PUFAs), angiotensin receptor blockers (ARBs), and pentoxifylline. The thiazolidinedione segment is expected to account for the largest share of the global market in 2018 owing to its high efficacy and safety profile. Based on application, hospitals and clinics are expected to account for the largest share of the global market in 2018 owing to increased awareness about available treatments for fatty liver disease among patients and healthcare professionals alike. Geographically, North America dominates the global fatly liver treatment market followed by Europe due with presence of large number Fatty Liver Disease population base .
Product Definition:
Fatty liver is a reversible condition in which large vacuoles of fat accumulate in the liver cells. The main symptom is jaundice, but there may also be abdominal pain, nausea, and vomiting. Treatment focuses on reducing the amount of fat in the liver. This can be done by diet and exercise or by medication.
Thiazolidinedione:
Thiazolidinedione is a drug that reduces the production of fat in the liver. It works by decreasing the amount of fat and sugar released into the bloodstream. Thiazolidinedione is used to treat fatty liver disease, steatosis, and hepatic lipidosis. Fatty liver or steatosis refers to an abnormal accumulation of fats in hepatocytes which may lead to fibrosis or even death if left unattended.
Vitamin E:
Vitamin E is a fat-soluble vitamin required to maintain liver function. It helps in the removal of toxins from the body and also aids in cell growth & development. Vitamin E deficiency leads to poor functioning of the liver, which may result in fatty livers or livers with steatosis (fatty liver).
Application Insights:
The others segment held the largest share of over 60.0% in 2017. The application includes home treatment, where patients are advised to use diet and exercise for weight loss and maintenance. Patients with non-alcoholic steatohepatitis (NASH) are usually recommended a low-calorie diet that reduces the intake of fatty foods as they may trigger inflammation in the liver cells, which is harmful to patient health.
Fatty liver disease is most common among people who drink alcohol or engage in other unhealthy habits such as smoking or excessive consumption of fast food chains across the globe owing to increased exposure to toxins such as bile acids and aldehydes found in alcoholic drinks like beer and wine respectively. These factors have ledto an increasein demand for effective natural treatments that help treat NASH without any side effects at all, thereby driving market growth over the forecast period (2017 - 2030).
Regional Analysis:
North America dominated the global market in 2017 owing to a high prevalence of obesity and diabetes. According to the International Diabetes Federation, around 60% of diabetic patients in North America are obese or overweight. The region is expected to witness significant growth over the forecast period due to increasing awareness about fatty liver disease treatment options and rising healthcare expenditure.
Asia Pacific is expected to grow at a lucrative rate over the forecast period owing with growing medical tourism industry in countries such as India, China, Japan, Malaysia & Singapore. Availability of effective treatments for free on prescription will also boost demand for pentoxifylline based products which are sold widely across these countries due health benefits associated with it rather than profit motive as it is done within developing economies worldwide.
Growth Factors:
- Increasing prevalence of fatty liver disease
- Growing awareness about the health risks associated with fatty liver disease
- Rising demand for effective and safe fatty liver treatment options
- Technological advancements in the field of fatty liver treatment
- increasing research and development investments for novel therapies for treating fatty liver
Scope Of The Report
Report Attributes
Report Details
Report Title
Fatty Liver Treatment Market Research Report
By Type
Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers, Pentoxifylline
By Application
Hospitals and Clinics, Others
By Companies
Cardax, Daewoong, Roche, Glenmark, GW, Limerick BioPharma, Merck, Novartis, Orchid, AstraZeneca
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
200
Number of Tables & Figures
140
Customization Available
Yes, the report can be customized as per your need.
Global Fatty Liver Treatment Market Report Segments:
The global Fatty Liver Treatment market is segmented on the basis of:
Types
Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers, Pentoxifylline
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals and Clinics, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Cardax
- Daewoong
- Roche
- Glenmark
- GW
- Limerick BioPharma
- Merck
- Novartis
- Orchid
- AstraZeneca
Highlights of The Fatty Liver Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Thiazolidinedione
- Vitamin E
- Metformin Statins
- Polyunsaturated Fatty Acids
- Angiotensin Receptor Blockers
- Pentoxifylline
- By Application:
- Hospitals and Clinics
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Fatty Liver Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
There is no one-size-fits-all answer to this question, as the best fatty liver treatment will vary depending on the individual's symptoms and medical history. However, some common treatments for fatty liver include diet and lifestyle changes, medications such as statins or fibric acid supplements, and surgery.
Some of the major players in the fatty liver treatment market are Cardax, Daewoong, Roche, Glenmark, GW, Limerick BioPharma, Merck, Novartis, Orchid, AstraZeneca.
The fatty liver treatment market is expected to register a CAGR of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Fatty Liver Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Fatty Liver Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Fatty Liver Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Fatty Liver Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Fatty Liver Treatment Market Size & Forecast, 2018-2028
4.5.1 Fatty Liver Treatment Market Size and Y-o-Y Growth
4.5.2 Fatty Liver Treatment Market Absolute $ Opportunity
Chapter 5 Global Fatty Liver Treatment Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Fatty Liver Treatment Market Size Forecast by Type
5.2.1 Thiazolidinedione
5.2.2 Vitamin E
5.2.3 Metformin Statins
5.2.4 Polyunsaturated Fatty Acids
5.2.5 Angiotensin Receptor Blockers
5.2.6 Pentoxifylline
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Fatty Liver Treatment Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Fatty Liver Treatment Market Size Forecast by Applications
6.2.1 Hospitals and Clinics
6.2.2 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Fatty Liver Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Fatty Liver Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Fatty Liver Treatment Analysis and Forecast
9.1 Introduction
9.2 North America Fatty Liver Treatment Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Fatty Liver Treatment Market Size Forecast by Type
9.6.1 Thiazolidinedione
9.6.2 Vitamin E
9.6.3 Metformin Statins
9.6.4 Polyunsaturated Fatty Acids
9.6.5 Angiotensin Receptor Blockers
9.6.6 Pentoxifylline
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Fatty Liver Treatment Market Size Forecast by Applications
9.10.1 Hospitals and Clinics
9.10.2 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Fatty Liver Treatment Analysis and Forecast
10.1 Introduction
10.2 Europe Fatty Liver Treatment Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Fatty Liver Treatment Market Size Forecast by Type
10.6.1 Thiazolidinedione
10.6.2 Vitamin E
10.6.3 Metformin Statins
10.6.4 Polyunsaturated Fatty Acids
10.6.5 Angiotensin Receptor Blockers
10.6.6 Pentoxifylline
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Fatty Liver Treatment Market Size Forecast by Applications
10.10.1 Hospitals and Clinics
10.10.2 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Fatty Liver Treatment Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Fatty Liver Treatment Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Fatty Liver Treatment Market Size Forecast by Type
11.6.1 Thiazolidinedione
11.6.2 Vitamin E
11.6.3 Metformin Statins
11.6.4 Polyunsaturated Fatty Acids
11.6.5 Angiotensin Receptor Blockers
11.6.6 Pentoxifylline
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Fatty Liver Treatment Market Size Forecast by Applications
11.10.1 Hospitals and Clinics
11.10.2 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Fatty Liver Treatment Analysis and Forecast
12.1 Introduction
12.2 Latin America Fatty Liver Treatment Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Fatty Liver Treatment Market Size Forecast by Type
12.6.1 Thiazolidinedione
12.6.2 Vitamin E
12.6.3 Metformin Statins
12.6.4 Polyunsaturated Fatty Acids
12.6.5 Angiotensin Receptor Blockers
12.6.6 Pentoxifylline
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Fatty Liver Treatment Market Size Forecast by Applications
12.10.1 Hospitals and Clinics
12.10.2 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Fatty Liver Treatment Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Fatty Liver Treatment Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Fatty Liver Treatment Market Size Forecast by Type
13.6.1 Thiazolidinedione
13.6.2 Vitamin E
13.6.3 Metformin Statins
13.6.4 Polyunsaturated Fatty Acids
13.6.5 Angiotensin Receptor Blockers
13.6.6 Pentoxifylline
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Fatty Liver Treatment Market Size Forecast by Applications
13.10.1 Hospitals and Clinics
13.10.2 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Fatty Liver Treatment Market: Competitive Dashboard
14.2 Global Fatty Liver Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Cardax
14.3.2 Daewoong
14.3.3 Roche
14.3.4 Glenmark
14.3.5 GW
14.3.6 Limerick BioPharma
14.3.7 Merck
14.3.8 Novartis
14.3.9 Orchid
14.3.10 AstraZeneca
